Show simple item record

dc.creatorĐurasinović, Vladislava T.
dc.creatorMihaljević, Biljana
dc.creatorŠipetić-Grujičić, Sandra B.
dc.creatorIgnjatović, Svetlana
dc.creatorTrajković, Goran
dc.creatorTodorović-Balint, Milena R.
dc.creatorAntić, Darko
dc.creatorBila, Jelena S.
dc.creatorAnđelić, Bosko M.
dc.creatorJelicić, Jelena J.
dc.creatorVuković, Vojin M.
dc.creatorNikolić, Aleksandra M.
dc.creatorKlek, Stanislaw
dc.date.accessioned2019-09-02T12:08:19Z
dc.date.available2019-09-02T12:08:19Z
dc.date.issued2018
dc.identifier.issn0941-4355
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/3236
dc.description.abstractIntroduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D lt 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D lt 19.6 nmol/l had a significantly shorter PFS.en
dc.publisherSpringer, New York
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175036/RS//
dc.rightsrestrictedAccess
dc.sourceSynthetic Communications
dc.subject25(OH)D levelen
dc.subjectLymphomaen
dc.title25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?en
dc.typearticle
dc.rights.licenseARR
dcterms.abstractAнђелић, Боско М.; Јелицић, Јелена Ј.; Николић, Aлександра М.; Клек, Станислаw; Била, Јелена С.; Вуковић, Војин М.; Игњатовић, Светлана; Ђурасиновић, Владислава Т.; Михаљевић, Биљана; Трајковић, Горан; Aнтић, Дарко; Шипетић-Грујичић, Сандра Б.; Тодоровић-Балинт, Милена Р.;
dc.citation.volume26
dc.citation.issue8
dc.citation.spage2825
dc.citation.epage2832
dc.citation.other26(8): 2825-2832
dc.citation.rankM21
dc.identifier.wos000436242800037
dc.identifier.doi10.1007/s00520-018-4101-9
dc.identifier.pmid29511954
dc.identifier.scopus2-s2.0-85049436913
dc.identifier.rcubconv_4143
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record